OncoMatch/Clinical Trials/NCT07645625

Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer

Is NCT07645625 recruiting? Yes, currently enrolling (Oct 2026). This Phase 4 trial studies Early discontinuation of Pembrolizumab with or without Bevacizumab for cervical cancer.

Treatment: Early discontinuation of Pembrolizumab with or without Bevacizumab — This is a nationwide, multicenter, registry-based prospective cohort study to assess real-world effectiveness of treatment with a pembrolizumab containing regimen in persistent, recurrent, or metastatic cervical cancer. Patients in the observation cohort continue treatment according to standard of care. In the discontinuation cohort, patients discontinue their maintenance treatment with pembrolizumab (with or without discontinuation of bevacizumab). Patients may choose to discontinue pembrolizumab prematurely (with or without discontinuation of bevacizumab) if they achieve a confirmed CR or a confirmed PR to treatment, or on patient's request or due to toxicity. If an eligible patient chooses not to discontinue treatment early they will remain in the observation cohort. The duration of the trial for the individual patient will be until two years from the start of treatment. Survival follow-up will continue for a maximum of 10 years